Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned an average rating of “Buy” from the five brokerages that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $7.80.

Several research firms recently weighed in on TCRX. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 target price on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Morgan Stanley reiterated an “overweight” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, March 7th.

TScan Therapeutics Trading Down 1.3%

TScan Therapeutics stock opened at $1.53 on Friday. The company’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $2.07. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 12 month low of $1.02 and a 12 month high of $8.51. The stock has a market cap of $86.58 million, a P/E ratio of -1.44 and a beta of 0.98.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, sell-side analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Lynx1 Capital Management Lp bought 1,388,794 shares of the business’s stock in a transaction dated Monday, May 19th. The stock was bought at an average price of $1.20 per share, for a total transaction of $1,666,552.80. Following the completion of the purchase, the insider now owns 6,746,141 shares of the company’s stock, valued at approximately $8,095,369.20. The trade was a 25.92% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.35% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC increased its holdings in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after purchasing an additional 4,852 shares in the last quarter. Tocqueville Asset Management L.P. increased its holdings in shares of TScan Therapeutics by 26.8% in the fourth quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company’s stock valued at $793,000 after purchasing an additional 55,140 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics during the 4th quarter valued at $32,000. JPMorgan Chase & Co. raised its position in shares of TScan Therapeutics by 109.9% during the 4th quarter. JPMorgan Chase & Co. now owns 66,756 shares of the company’s stock valued at $203,000 after acquiring an additional 34,951 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.